Search across the field

Boltz-2 v0.4 release — 18% accuracy gain on PoseBusters benchmark

Improved affinity head, new confidence calibration. Inference latency unchanged. Drop-in replacement for v0.3.

RFdiffusion-AA paper published — all-atom de novo protein binder design

Baker lab. Atomic-accuracy binder generation against small-molecule targets. Benchmarks vs. AlphaProteo.

AlphaProteo: benchmarks show 47% binding-affinity gain over RFdiffusion on viral targets

Six-target head-to-head. Binders tested via BLI + yeast display.

Arvinas ARV-471 Phase 3 primary endpoint met in HR+ breast cancer

VERITAC-2 topline: statistically significant PFS improvement vs. fulvestrant. First oral PROTAC to hit Phase 3.

Recursion REC-994 Phase 2 interim: dose-response trend, safety profile clean

Cerebral cavernous malformation, 60-patient readout. Data support Phase 3 planning for H2 2026.

Xaira IND filing — AI-designed antibody for autoimmune indication

Isomorphic Labs announces first IND-enabling study for AI-designed oncology candidate

Structure-based design via AlphaFold3 + proprietary generative chemistry. Target undisclosed.

Insilico signs multi-target AI drug discovery deal with Menarini Group

Schrödinger reports Q1 platform revenue up 18% on AI-driven licensing deals